AI Summary
TXG reported Q4 2025 revenue of $166 million, up 11% sequentially. Instruments revenue fell 36% YoY, though grew 29% sequentially. Consumables revenue increased by 6% YoY, totaling $141.7 million. Full year 2025 revenue decreased by 2% after an adjustment for settlements. TXG has $520 million in cash and equivalents as of year-end 2025.
Sentiment Rationale
The moderate revenue growth in consumables may not outweigh declines in instruments revenue, reflecting a mixed performance. Expectations should remain tempered given the historical context where similar patterns have led to stagnant or reduced stock prices.
Trading Thesis
The immediate focus will likely be on the stock's reaction post-announcement and during the upcoming J.P. Morgan Healthcare Conference, suggesting a potential for volatility in the short-term.
Market-Moving
- TXG reported Q4 2025 revenue of $166 million, up 11% sequentially.
- Instruments revenue fell 36% YoY, though grew 29% sequentially.
- Consumables revenue increased by 6% YoY, totaling $141.7 million.
Key Facts
- TXG reported Q4 2025 revenue of $166 million, up 11% sequentially.
- Instruments revenue fell 36% YoY, though grew 29% sequentially.
- Consumables revenue increased by 6% YoY, totaling $141.7 million.
- Full year 2025 revenue decreased by 2% after an adjustment for settlements.
- TXG has $520 million in cash and equivalents as of year-end 2025.
Companies Mentioned
- ABCL (ABCL)
- ILMN (ILMN)
- PACB (PACB)
Earnings
The financials provided are preliminary, leaving room for adjustments, which could significantly influence investor perception and market performance if results change.